Vestbo Jørgen, Lange Peter
Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.
Institute of Public Health, University of Copenhagen, Copenhagen, Denmark; Department of Respiratory Medicine, Hvidovre University Hospital, Hvidovre, Denmark.
ERJ Open Res. 2015 May 6;1(1). doi: 10.1183/23120541.00011-2015. eCollection 2015 May.
Exacerbations have significant impact on the morbidity and mortality of patients with chronic obstructive pulmonary disease. Most guidelines emphasise prevention of exacerbations by treatment with long-acting bronchodilators and/or anti-inflammatory drugs. Whereas most of this treatment is evidence-based, it is clear that patients differ regarding the nature of exacerbations and are likely to benefit differently from different types of treatment. In this short review, we wish to highlight this, suggest a first step in differentiating pharmacological exacerbation prevention and call for more studies in this area. Finally, we wish to highlight that there are perhaps easier ways of achieving similar success in exacerbation prevention using nonpharmacological tools.
急性加重对慢性阻塞性肺疾病患者的发病率和死亡率有重大影响。大多数指南强调通过使用长效支气管扩张剂和/或抗炎药物进行治疗来预防急性加重。虽然这种治疗大多基于证据，但很明显，患者在急性加重的性质方面存在差异，并且可能从不同类型的治疗中获得不同程度的益处。在这篇简短的综述中，我们希望强调这一点，提出区分药物性急性加重预防的第一步，并呼吁在该领域开展更多研究。最后，我们希望强调，或许有更简便的方法利用非药物手段在预防急性加重方面取得类似的成效。
